The effect of oral hormone therapy on the metabolome of postmenopausal women is profound. Different hormone therapy regimens result in discordant metabolomic effects that impact the risk for coronary heart disease, reports a study led by Raji Balasubramanian, associate professor in the School of Public Health and Health Sciences, University of Massachusetts, Amherst.
The study, based on the assessment of 481 metabolites in 934 women who participated in the Women’s Health Initiative hormone therapy (WHI-HT) trials, is reported in the article “Metabolomic Effects of Hormone Therapy and Associations with Coronary Heart Disease among Postmenopausal Women,” published in the journal Circulation: Genomic and Precision Medicine.
